Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer
The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with on...